Cyclic AMP-specific phosphodiesterase 4 (PDE4), which is an integral component of NMDA receptor-mediated cAMP signaling, is involved in the mediation of memory processes. Given that NMDA receptors also mediate MEK/mitogen-activated protein kinase (MAPK, ERK) signaling, which is involved in synaptic plasticity, and that some PDE4 subtypes are phosphorylated and regulated by ERK, it was of interest to determine if PDE4 is involved in MEK/ERK signaling-mediated memory. It was found that rolipram, a PDE4-selective inhibitor, reversed the amnesic effect in the radial-arm maze test of the MEK inhibitor U0126 administered into the CA1 subregion of the rat hippocampus. Consistent with this, rolipram, either by peripheral administration or direct intra-CA1 infusion, enhanced the retrieval of long-term memory impaired by intra-CA1 infusion of U0126 using the step-through inhibitory avoidance test. The same dose of rolipram did not affect U0126-induced reduction of phospho-ERK1/2 levels in the CA1 subregion. However, in primary cultures of rat cerebral cortical neurons, pretreatment with U0126 increased PDE4 activity; this was correlated with the U0126-induced reduction of phospho-ERK1/2 levels. These results suggest that MEK/ERK signaling plays an inhibitory role in regulating PDE4 activity in the brain; this may be a novel mechanism by which MEK/ERK signaling mediates memory. PDE4 is likely to be an important link between the cAMP/PKA and MEK/ERK signaling pathways in the mediation of memory.
INTRODUCTION
Cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4), which catalyzes hydrolysis of cAMP, plays a critical role in the control of intracellular cAMP concentrations (Houslay, 2001) . PDE4 has been shown to be an important mediator of memory processes associated with N-methyl-D-aspartate (NMDA) receptor-mediated signaling. Pretreatment with rolipram, a PDE4-selective inhibitor, reverses the amnesic effect of the NMDA receptor antagonist MK-801 in rats and enhances NMDA-induced increases in cAMP in rat cerebral cortical neurons Suvarna and O'Donnell, 2002) . This is supported by recent findings that rolipram blocks memory deficits induced by heterozygous deficiency of cAMP-responsive element binding protein (CREB)-binding protein (CBP; Bourtchouladze et al, 2003) , and that PDE4 is involved in the induction of long-term potentiation (LTP) in the CA1 subregion of the hippocampus (Ahmed and Frey, 2003) , an area where PDE4 is highly expressed (McPhee et al, 2001) . These results indicate that PDE4 in the hippocampus may play an important role in cAMP signaling in the mediation of memory processes.
Cyclic AMP/protein kinase A (PKA) signaling has been shown to mediate synaptic plasticity and memory (Frey et al, 1993; Izquierdo et al, 2002) . Inhibition of cAMP/PKA signaling impairs memory, especially long-term memory (Koh et al, 2002) ; stimulation of this pathway enhances memory (Barad et al, 1998; . Similar to cAMP signaling, the MEK/mitogen-activated protein kinase (MAPK, ERK) pathway also has been shown to be involved in the mediation of synaptic plasticity and memory (Adams and Sweatt, 2002; Schafe et al, 2000; Sharma et al, 2003) . Activation of ERK signaling enhances the induction of longterm-synaptic facilitation as well as long-term memory (Purcell et al, 2003) . Conversely, inhibition of ERK signaling in the dorsal hippocampus blocks the formation of longterm memory, but not acquisition of short-term memory (Blum et al, 1999; Sharma et al, 2003) . Further, both signaling pathways interact with each other. Increases in cAMP levels stimulate or inhibit ERK signaling, depending on cell types. In PC12 or CHO-K1 cells, cAMP increases ERK activity; in C6 or NB2A cells, cAMP inhibits ERK activity (Qiu et al, 2000) . Conversely, in F442A cells, activation of ERK with epidermal growth factor (EGF) increases cAMP by inhibiting a PDE4 isoenzyme (Hoffmann et al, 1999) . Consistently, crosstalk exists between cAMP and ERK signaling in the CA1 subregion of the hippocampus (Patterson et al, 2001; Stork and Schmitt, 2002) , which is involved in the mediation of synaptic plasticity (Patterson et al, 2001; Roberson et al, 1999) and ERK signalingmediated long-term memory (Blum et al, 1999) . Further, PDE4 isoemzymes are phosphorylated and regulated by ERK2. In COS1 cells, the long-form PDE4 isoenzymes such as PDE4D3 and PDE4D5 are inhibited by ERK2 phosphorylation, whereas the short-form PDE4 such as PDE4B2 is activated by ERK2 phosphorylation . While it is not known whether ERK signaling affects PDE4 activity in neuronal cells, these results indicate that PDE4 may play an essential role in crosstalk between the two signaling pathways; PDE4 inhibitors may reverse memory deficits induced by inhibition of ERK signaling. To address these questions, we examined whether rolipram would alter memory impairments produced by bilateral infusion of the MEK inhibitor U0126 into the CA1 subregion of the hippocampus. Memory was assessed in rats using the eightarm radial maze and step-through inhibitory avoidance tests. In addition, the interaction between MEK and PDE4 inhibition was assessed by Western blotting for ERK and phospho-ERK. PDE4 activity was assayed in cerebral cortical neurons treated with U0126.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (250-300 g) were housed individually in plastic cages in a room that was kept at a constant temperature (22-231C) and on a 12-h on/12-h off light cycle (lights on at 0600 h). Water and food were freely available, except for the rats used for the radial-arm maze task; for these rats, food was restricted to 16 g per day after test sessions, so as to maintain body weights at 80-85% of free-feeding weights. All experiments were carried out according to the 'NIH Guide for the Care and Use of Laboratory Animals' (revised 1996) and were approved by the Animal Care and Use Committee at the University of Tennessee Health Science Center.
Surgery
All surgery was performed under aseptic conditions. Rats were anesthetized (50 mg/kg ketamine and 6 mg/kg xylazine) and placed in a stereotaxic holder (Stoelting, Wood Dale, IL). 22-Gauge guide cannulae (22-gauge) (Plastics One, Roanoke, VA) were implanted bilaterally into the CA1 subregion of the hippocampus using the following coordinates: AP, À3.3 mm from Bregma; ML, 72.0 mm from the midline; DV, À2.5 mm from dura (Blum et al, 1999; Paxinos and Watson, 1986) . At 1 week after surgery, rats resumed daily sessions (the radial-arm maze task) or started training (the step-through task). Following completion of the testing, sites of cannula implantation were verified histologically.
The Radial-Arm Maze Test
The test was performed as described previously . Rats were trained twice a day to locate food pellets in each of four randomly selected arms in the eight-arm radial maze (each arm was 60 cm long, 10 cm wide, and 12 cm high; the maze was elevated 70 cm above the floor). Four parameters were recorded: (1) working memory errors, that is, entries into baited arms that had already been visited during the same trial; (2) reference memory errors, that is, entries into unbaited arms; (3) total arm entries; (4) the test duration, that is, the time spent in the collection of all the pellets in the maze. When the working memory error was zero and the average reference memory error was less than 1 in five successive trials, the drug tests were initiated.
Rolipram (Schering AG, Berlin, Germany) was dissolved in saline containing 1% dimethyl sulfoxide (DMSO; for i.p. injections) or DMSO (for intra-CA1 infusions); U0126 (Promega, Madison, WI) was dissolved in DMSO. U0126 (4 mg/side) was infused bilaterally into the CA1 subregion of the hippocampus in a volume of 0.5 ml/side in a 2-min period using a syringe pump; the 28-gauge infusion cannulae, which were 1 mm longer than the guide cannulae, were left in place for an additional minute to permit diffusion. After 30 min, this treatment was repeated along with an injection of rolipram (0.1 mg/kg, i.p.) or its vehicle. Behavioral experiments were performed 30 min later in a lighted, quiet room that contained several extra-maze visual cues. The frequency of working and reference memory errors was determined. The frequency was calculated as the number of working or reference memory errors divided by total number of entries into the arms.
The Inhibitory Avoidance Test
The test was performed as described previously . During training, the rat was placed in the illuminated compartment of a two-compartment chamber (Model E10-16SC, Coulbourn Instruments, Allentown, PA), facing away from the closed guillotine door for 1 min, after which the door was raised. After the rat entered the darkened side, the door was closed and a 0.5 mA electric foot-shock was administered for 3 s. After 24 h, U0126 (4 mg/side into the CA1 subregion, twice; total dose, 16 mg) and rolipram (0.1 mg/kg, i.p.) were administered as described above. At 30 min after i.p. injection of rolipram, the rat was again placed on the illuminated side, with the guillotine door open. For intra-CA1 infusion, rolipram (15 mg/side; total dose, 30 mg) was given 10 min after the second CA1 infusion of U0126, which was given 30 min prior to the test. The latency for entering the darkened compartment was recorded for up to 180 s. At 48 h after the initial training, retention was tested again without any additional treatments.
Tissue Preparation and Western Blots
CA1 tissue of the hippocampus from a separate group of rats was used for ERK1/2 activity analysis. At 30 min after the second CA1 infusion of U0126 plus vehicle or rolipram (0.1 mg/kg, i.p.) as described above, rats were decapitated, their brains removed, and the hippocampi dissected. Bilateral CA1 tissue was punched with a plastic pipette (inner diameter, 0.2 mm), sonicated for 10 s in 300 ml of 2% SDS, and centrifuged at 15 000g for 30 min at 41C. The resulting supernatant was removed, an aliquot was taken for protein assay, and the remainder was stored at À801C until use.
Gel electrophoresis and immunoblotting were performed as described previously (Chandler et al, 2001) . Aliquots of the frozen supernatant were diluted with 2 Â electrophoresis sample buffer (50 mM Tris HCl, pH 6.7, 4% w/v glycerol, 4% SDS, 1% 2-mercaptoethanol, and 0.02 mg/ml bromphenol blue) and then boiled for 10 min; 20 mg protein samples were separated using 7.5% SDS-polyacrylaminde gels and transferred to Immobilon-P membranes (Millipore, Bedford, MA). After transfer, the membranes were blocked in PBST buffer containing 5% nonfat dried milk (Carnation) and 1% bovine serum albumin for 1 h at room temperature, washed and incubated overnight at 41C with anti-phospho-ERK1/2 antibody (1 : 1000; Cell Signaling Technology, Inc., Beverly, MA). The membranes were then washed and incubated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (1 : 2000; Cell Signaling Technology, Inc., Beverly, MA). The antigen-antibodyperoxidase complex was detected by enhanced chemiluminescence and visualized by exposure to Hyperfilm ECL (Amersham Biosciences Corp., Piscataway, NJ). The membranes were then washed with PBST and stripped, blocked, and reprobed with anti-ERK antibody (1 : 1000; Cell Signaling Technology, Inc., Beverly, MA) as described above. Exposed films were analyzed and quantified by computer-assisted densitometry; comparisons between treatment conditions were carried out within individual gels/immunoblots.
ERK and PDE4 Activity in Neuronal Cultures
Cerebral cortical cultures were prepared from newborn rat pups and treated as described previously (Chandler et al, 2001) . Cortical cultures were washed twice with 1.5 ml of HEPES buffer (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 100 nM glycine, 15 mM glucose, and 25 mM HEPES, pH 7.4) and incubated at 371C with 1 ml HEPES buffer containing 1 mM TTX. After a 30-min incubation, U0126 (0.01, 0.1, 1, or 10 mM) or vehicle (DMSO) was added. The cultures were allowed to incubate for an additional 30 min (for PDE4 assay) or 60 min (for Western blots) before the cells were scraped into 100 ml of RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS). Homogenates from triplicate dishes were combined, sonicated (B5 s), and centrifuged at 15 000g for 30 min at 41C. The resulting supernatant was stored at À201C for subsequent determination of phospho-ERK/ERK (as described above), PDE4 activity (Zhang et al, 2002) , and protein concentration using the bicinchoninic acid assay (Pierce Biotechnology, Inc., Rockford, IL). For the PDE4 determination, the supernatant was assayed in the absence (total PDE activity) and presence (rolipram-insensitive PDE or non-PDE4 activity) of 10 mM rolipram; PDE4 (rolipramsensitive PDE) activity was determined by subtracting non-PDE4 activity from total PDE activity (Zhang et al, 2002) .
Statistical Analysis
All data were analyzed by one-way analyses of variance (ANOVA) followed by Newman-Keuls tests for post hoc comparisons of individual means. The r-values were calculated using linear regression.
RESULTS
Rolipram Reversed Memory Deficit Induced by Intra-CA1 Infusion of U0126 in the Radial-Arm Maze Test
To determine the involvement of PDE4 in ERK signalingmediated memory, the effects of rolipram, a selective PDE4 inhibitor, on radial-arm maze behavior was examined; this measures hippocampus-dependent memory. Rats were implanted with cannula guides into the CA1 subregion of the hippocampus. Histological verification showed high localization of the cannula placements within the CA1 subregion (Figure 1a, b) . U0126, which was directly infused into the CA1 subregion of the hippocampus at a total dose of 16 mg (4 mg/side bilaterally, two infusions), produced a significant increase in reference memory errors (po0.01). This effect of U0126 was antagonized by rolipram in a dosedependent manner (F 3,29 ¼ 5.69, po0.01; Figure 2a ). The treatments did not significantly affect the working memory errors (Figure 2b ) or alter the exploration time except for the higher dose of rolipram (plus U0126), which increased the exploration time (po0.05; Figure 2c ). The latter is consistent with a previous study . In addition, the same doses of rolipram alone did not affect the radial-arm maze performance (data not shown). These results indicate that rolipram specifically enhances longterm memory impaired by U0126.
Rolipram Enhanced Retrieval of Long-Term Memory Impaired by U0126 Infused into Hippocampal CA1 in the Step-Through Inhibitory Avoidance Test
To confirm the effects of rolipram on the U0126-induced memory deficit, the step-through inhibitory avoidance test was used to assess retrieval of long-term memory; this also measures hippocampus-dependent memory. Rolipram was given either i.p. or bilaterally into the CA1 region of the hippocampus. At 24 h after initial training, U0126-treated rats did not show a significant reduction of retention because of the relatively low baseline of the vehicle control. However, rolipram treatment, either i.p. or intra-CA1, markedly increased the retention (Figure 3a, b) . At 48 h after training, vehicle-treated rats almost completely recovered from memory impairment; U0126-treated rats, however, showed a significant reduction of retention. Rolipram, at a dose of 0.1 mg/kg, i.p., reversed the amnesic effect of U0126 (F 2,24 ¼ 4.51, po0.05; Figure 3a) . A similar antagonism was observed when rolipram (15 mg/side) was administered directly into the CA1 subregion of the hippocampus (F 2,12 ¼ 7.12, po0.01; Figure 3b ).
Rolipram Did Not Alter U0126-Induced Reduction of Phospho-ERK Levels in the CA1 Subregion
The behavioral data indicate a functional link between ERK and cAMP signaling pathways in the mediation of long-term memory, in which PDE4 is likely to be involved. In order to investigate this possible interaction, the phospho-ERK level was examined in the CA1 subregion of the hippocampus of rats treated with U0126 alone or in combination with doses of rolipram that were effective in the behavioral tests. Bilateral infusion of U0126 into the CA1 subregion caused a Figure 1 Infusion sites for the bilateral hippocampal CA1 drug administration in (a) the radial-arm maze and (b) the step-through avoidance tests. Coronal sections of the rat brain at À2.8, À3.3, and À3.6 mm from Bregma (Paxinos and Watson, 1986) are shown with CA1-3 subregions and dentate gyrus (DG) labeled. The treatments did not alter the average exploration time, except U0126 plus 0.1 mg/kg rolipram, which increased the exploration time. U0126 (4 mg/side, bilateral CA1 infusion twice; total, 16 mg) and rolipram (0.01 and 0.1 mg/kg, i.p.) were given as described in Materials and Methods. Data shown are means7SE from 10 rats. ANOVA and post hoc Newman-Keuls tests revealed the following differences: * po0.05, ** po0.01 vs the vehicle (Veh; DMSO þ saline)-treated group; # po0.05 vs the U0126 þ saline group.
Inhibition of the PDE4 enzyme reverses memory deficits H-T Zhang et al significant decrease in the levels of both phospho-ERK1 (P44 phospho-ERK; F 2,15 ¼ 37.22, po0.0001) and phospho-ERK2 (P42 phospho-ERK; F 2,15 ¼ 21.31, po0.0001; Figure  4a , c, d); by contrast, total ERK levels were not changed (Figure 4b, e) . Rolipram did not alter U0126-induced inhibition of phospho-ERK1/2 in the CA1 subregion, indicating that the effect of rolipram on U0126-impaired memory did not result from a direct effect on ERK activation.
U0126 Increased PDE4 Activity
Previous work has shown that ERK activation can result in a phosphorylation-mediated inhibition of PDE4 activity in F442A cells (Hoffmann et al, 1999) ; however, it was not known if such a mechanism was active in neurons. In order to determine whether MEK inhibition alters PDE4 activity, the effects of U0126 on phospho-ERK levels and PDE4 activity in primary cultures of rat cerebral cortical neurons were examined. U0126 (0.01-10 mM) reduced the levels of both phospho-ERK1 and phospho-ERK2 in the neurons in a concentration-dependent manner (F 4,15 Figure 5a , b). The same concentrations of U0126 that reduced phospho-ERK increased PDE4 activity in the neurons in a concentration-dependent manner (F 4,26 ¼ 8.55, po0.0005; Figure 5c ). The U0126-induced increase in PDE4 activity was negatively correlated with the U0126-induced reduction of phospho-ERK1 and phospho-ERK2 levels (r ¼ 0.92 and r ¼ 0.96, respectively; Figure 5d ). These results support the idea that ERK plays an inhibitory role in PDE4 activity in neurons.
DISCUSSION
Recent studies have shown that inhibition of hippocampal MEK/ERK signaling impairs synaptic plasticity as well as long-term memory formation (Davis et al, 2000; Kelly et al, 2003; Adams and Sweatt, 2002) . Consistent with this, in the present study, direct infusion of U0126, a specific MEK inhibitor (Hotokezaka et al, 2002) , into the CA1 subregion of the hippocampus, also impaired reference memory in the Rats were treated with U0126 and rolipram 24 h after initial training; test data shown were obtained 24 and 48 h posttraining. Administration of both drugs was the same as described above, except that of rolipram (15 mg/side, bilateral CA1 infusions), which was given 10 min after the second CA1 infusion of U0126. Data shown are means7SE from five to nine rats for each group. ANOVA and post hoc Newman-Keuls tests revealed the following differences: * po0.05, ** po0.01 vs the corresponding vehicle-treated group; # po0.05 vs the corresponding U0126 þ saline/DMSO group. radial-arm maze, an index of long-term memory . This indicates an important role of the MEK/ ERK signaling pathway in the CA1 subregion in the longterm memory process. To confirm this, we examined the retrieval of one-trial task in step-through inhibitory avoidance. ERK signaling is required for retrieval of longterm memory. The MEK inhibitor PD098059 infused into bilateral CA1 prior to the retention test blocks retrieval of long-term memory, but not short-term memory Izquierdo et al, 2000) . In agreement with this, U0126 administered by CA1 infusion prior to the retention test also impaired retrieval of long-term memory even if it was given 24 h before the second retention test (ie 48 after training). Rolipram blocked the effect of U0126 either by peripheral administration or CA1 infusion, indicating an enhancement of retrieval of long-term memory. It is not known how U0126 impaired the retrieval of one-trial inhibitory avoidance for such a long time after administration. However, a similar effect has been reported with the MEK inhibitor PD098059, which impairs long-term memory 21 h after administration (Walz et al, 1999) . The memoryenhancing effect of rolipram is only maintained for 60 min after single injection . However, rolipram, 24 h after injection, still blocked U0126-induced impairment of memory retrieval. This could be caused by rolipram reversal of U0126-induced disinhibition of PDE4 activity (see below).
Although it is established that cAMP/PKA signaling plays an essential role in the mediation of memory (Barad et al, 1998; Frey et al, 1993; Izquierdo et al, 2002; Koh et al, 2002; , the involvement of MEK/ERK signaling makes the memory mediation more complicated. To date, there is no evidence for the interaction of cAMP and ERK signaling in mediating memory. Thus, it is interesting that U0126-induced memory deficits were reversed by either peripheral or intra-CA1 administration of rolipram, a specific PDE4 inhibitor. These results suggest that PDE4 in the CA1 subregion of the hippocampus plays an important role in the memory process mediated by MEK/ ERK signaling.
It was possible that rolipram reversed U0126-induced memory deficit by antagonizing ERK inhibition by U0126 and/or inhibiting PDE4 activity. However, rolipram failed to affect U0126-induced decrease in phospho-ERK levels, indicating that it did not enhance memory via alteration of ERK activity. It is reported that rolipram enhances memory via inhibition of PDE4 and a subsequent increase in the cAMP concentration (Barad et al, 1998; . This appears to be the only known mechanism underlying the memory enhancement by rolipram. Therefore, PDE4 appears to be a connection between cAMP and ERK signaling pathways in mediating memory. This is further supported by in vitro studies. In COS-1 cells, ERK2 activation induces a phosphorylation-mediated inhibition of activity of transfected PDE4D3 and PDE4B1 Hoffmann et al, 1999) . This mechanism also appears to be active in neurons since it was demonstrated that MEK inhibition increased PDE4 activity in cerebral cortical neurons. The change in PDE4 activity was correlated with inhibition of ERK1/2, quantified by phospho-ERK1/2 levels. This suggests an inhibitory role of ERK signaling in PDE4 activity.
Mammalian PDE4 enzymes are encoded by four genes: PDE4A, PDE4B, PDE4C, and PDE4D (Houslay, 2001 ). While PDE4C is minimally expressed in the central nervous system, the other three PDE4 subtypes are highly expressed Correlation between PDE4 activity and phospho-ERK1/2. The cultured neurons were incubated with vehicle (Veh; DMSO) or U0126 for 30 min in the presence of TTX (1 mM), which was added 30 min prior to U0126. The control (Veh) PDE4 activity was 14.471.7 pmol/min/mg protein. Data shown are means7SE from four experiments for each group (b) or six to -10 experiments for each group except for the 0.01 and 0.1 mM U0126 groups, in which three experiments were used (c). ANOVA and post hoc Newman-Keuls comparisons revealed the following differences: **po0.01, ***po0.001 vs corresponding vehicle control.
thoughout the brain (Cherry and Davis, 1999; Perez-Torres et al, 2000) . However, the CA1 subregion of the rat hippocampus appears to express PDE4A and PDE4D at the highest levels, while PDE4B is expressed only at a low level in this structure (Perez-Torres et al, 2000) . Technical limitations prevented determining PDE4 activity in CA1 neurons, so primary cultures of cerebral cortical neurons, which express PDE4A, PDE4B, and PDE4D, were used (D 'Sa et al, 2002) . Since activation of ERK phosphorylates PDE4B, PDE4C, and PDE4D, but not PDE4A , it appears that PDE4A is not a component of U0126-stimulated PDE4 activity. In addition, ERK phosphorylation results in inhibition of only long-form PDE4 variants, but causes activation of short-form variants O'Donnell and Zhang, 2004) . Finally, PDE4 activity in the hippocampus is primarily attributed to PDE4D (Jin et al, 1999; Zhang et al, 2002) , suggesting that changes in PDE4 activity induced by ERK-mediated phosphorylation involve this subtype to the greatest extent. Given that the shortform PDE4D variants are either somewhat activated (PDE4D1) or not affected (PDE4D2 and PDE4D6) by ERK activation , the long-form PDE4Ds, including PDE4D3, 4D4, 4D5, and 4D7 (Wang et al, 2003; O'Donnell and Zhang, 2004) , could be the targets of ERK phosphorylation.
Taken together, the present results suggest that PDE4, as a critical regulator in the control of intracellular cAMP concentrations, provides a connection between cAMP/PKA and MEK/ERK signaling pathways. Given that inhibition of MEK/ERK signaling by U0126 increased PDE4 activity in neurons, MEK/ERK signaling may exert an inhibitory action on PDE4, which plays a major role in ERK-mediated memory processes. PDE4 inhibitors can reverse memory deficits induced by inhibition of either cAMP/PKA signaling or MEK/ERK signaling.
